Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab, a new trifunctional ...

There is no transcript available.

(BUSINESS WIRE )--Pharmanovia, a global Pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the ...

The agreement gives Pharmanovia the exclusive rights to bring to market, catumaxomab, a first-in-class, trifunctional bi-specific monoclonal antibody, indicated for the intraperitoneal treatment of ...

Background: Ascites and pleural effusion are well recognized complications of pancreatic diseases. Drug therapy of these is limited by high cost, prolonged hospitalization and failure rates ...

Effective treatment of ascites remains one of the most important aspects in the management of patients with decompensated cirrhosis, especially in those who are not candidates for liver ...

Allergic reaction to the silicone is rare in children and as a result very little experience has been reported on symptom and treatment. We presented a case involving a child who experienced prolonged ...

Catumaxomab received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) at its October 2024 meeting and if approved catumaxomab will be the only approved drug for ...

Catumaxomab Received a Positive Opinion From the EMA's Committee for Medicinal Products for Human Use (CHMP) at Its October 2024 Meeting and If ...

Cirrhosis is a progressive liver condition that often remains hidden in its early stages. The disease, marked by irreversible ...

Joseph Ambani, a Medical Doctor at GlowBar, has shared the top symptom for liver cancer which can be spotted during the early ...

If approved, Korjuny would become the only drug approved for the specific and cancer-directed treatment of malignant ascites, an abnormal accumulation of fluid in the peritoneal cavity that commonly ...